Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations
<i>S</i>-(+) enantiomer of ibuprofen (IBU) dexibuprofen (DXI) is known to be more potent than its <i>R</i>-(−) form and exhibits many advantages over the racemic mixture of IBU such as lower toxicity, greater clinical efficacy, and lesser variability in therapeutic effects. M...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/3/414 |